rFVIIa-induced changes of biomarkers
| Subjects . | Non-FVL carriers, n = 12 . | Heterozygous FVL carriers, n = 12 . | ||||
|---|---|---|---|---|---|---|
| Ct=0 . | Cpeak . | P . | Ct=0 . | Cpeak . | P . | |
| F1+2, nmol/L | 0.13 (0.09-0.19) | 0.18 (0.10-0.21) | .048 | 0.18 (0.10-0.20) | 0.23 (0.19-0.28) | .022 |
| TAT, ng/mL | <2.0 (<2.0-<2.0) | <2.0 (<2.0-2.65) | NS | <2.0 (<2.0-2.31) | 3.16 (2.05-3.60) | NS* |
| APC, pmol/L | 0.63 (0.50-1.20) | 2.93 (2.44-3.58) | .025 | 1.44 (1.21-2.08) | 9.09 (7.69-12.88) | 7 × 10−5 |
| D-dimer, mg/L | 0.28 (0.23-0.37) | 0.31 (0.25-0.44) | NS | 0.35 (0.26-0.44) | 0.43 (0.35-0.53) | NS |
| Subjects . | Non-FVL carriers, n = 12 . | Heterozygous FVL carriers, n = 12 . | ||||
|---|---|---|---|---|---|---|
| Ct=0 . | Cpeak . | P . | Ct=0 . | Cpeak . | P . | |
| F1+2, nmol/L | 0.13 (0.09-0.19) | 0.18 (0.10-0.21) | .048 | 0.18 (0.10-0.20) | 0.23 (0.19-0.28) | .022 |
| TAT, ng/mL | <2.0 (<2.0-<2.0) | <2.0 (<2.0-2.65) | NS | <2.0 (<2.0-2.31) | 3.16 (2.05-3.60) | NS* |
| APC, pmol/L | 0.63 (0.50-1.20) | 2.93 (2.44-3.58) | .025 | 1.44 (1.21-2.08) | 9.09 (7.69-12.88) | 7 × 10−5 |
| D-dimer, mg/L | 0.28 (0.23-0.37) | 0.31 (0.25-0.44) | NS | 0.35 (0.26-0.44) | 0.43 (0.35-0.53) | NS |
Data are presented as median and interquartile range. P values describe differences of peak values from baseline and were calculated using the paired Student t test or the Wilcoxon signed-rank test.
Cpeak, the highest plasma concentration measured within 8 hours after IV injection of 15 µg/kg rFVIIa; Ct=0, the plasma concentration measured at baseline; NS, not significant.
P = .030 before Bonferroni correction.